BFEC
BEAM icon

Benjamin F. Edwards & Company’s Beam Therapeutics BEAM Stock Holding History

Benjamin F. Edwards & Company’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$445K Buy
18,982
+18,598
+4,843% +$457K 0.01% 719
2024
Q1 		$13K Buy
384
+293
+322% +$9.13K ﹤0.01% 1627
2023
Q4 		$2K Hold
91
– – ﹤0.01% 1974
2023
Q3 		$2K Hold
91
– – ﹤0.01% 1655
2023
Q2 		$3K Hold
91
– – ﹤0.01% 1616
2023
Q1 		$3K Buy
91
+41
+82% +$1.62K ﹤0.01% 1618
2022
Q4 		$2K Hold
50
– – ﹤0.01% 1706
2022
Q3 		$2K Hold
50
– – ﹤0.01% 1692
2022
Q2 		$2K Sell
50
-100
-67% -$3.98K ﹤0.01% 1665
2022
Q1 		$9K Hold
150
– – ﹤0.01% 1381
2021
Q4 		$12K Sell
150
-200
-57% -$17.1K ﹤0.01% 1333
2021
Q3 		$30K Buy
+350
New +$35.2K ﹤0.01% 1140

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Benjamin F. Edwards & Company's BEAM Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its Beam Therapeutics (BEAM) stake by 4,843% in Q2 2024, buying an estimated $457K and bringing the position to 18,982 shares worth $445K. The position accounts for 0.01% of the portfolio, ranked #719.

Benjamin F. Edwards & Company first reported a position in BEAM in Q3 2021 and has held it in 12 quarters since. 214 funds tracked by Wall St. Rank hold BEAM as of Q2 2024.

  • Benjamin F. Edwards & Company held 18,982 shares of Beam Therapeutics worth $445K as of Q2 2024.
  • Benjamin F. Edwards & Company bought 18,598 Beam Therapeutics shares in Q2 2024, an estimated $457K.
  • Beam Therapeutics made up 0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #719 holding.
  • Benjamin F. Edwards & Company first reported a position in Beam Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • 214 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.